Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Humacyte's Enterprise Value is $292.71 Mil.
Humacyte's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-67.21 Mil. Therefore, Humacyte's EV-to-EBIT ratio for today is -4.36.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Humacyte's Enterprise Value is $292.71 Mil.
Humacyte's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-59.97 Mil. Therefore, Humacyte's EV-to-EBITDA ratio for today is -4.88.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Humacyte's Enterprise Value is $292.71 Mil.
Humacyte's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.52 Mil. Therefore, Humacyte's EV-to-Revenue ratio for today is 566.18.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Humacyte's Enterprise Value is $292.71 Mil.
Humacyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-100.79 Mil. Therefore, Humacyte's EV-to-FCF ratio for today is -2.90.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Humacyte Enterprise Value Historical Data
The historical data trend for Humacyte's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Humacyte's Enterprise Value
For the Biotechnology subindustry, Humacyte's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humacyte's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Humacyte's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Humacyte's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Humacyte's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humacyte (NAS:HUMA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Humacyte's current Enterprise Value is $292.71 Mil.
Humacyte's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.21 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Humacyte's current Enterprise Value is $292.71 Mil.
Humacyte's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.97 Mil.
Humacyte's current Enterprise Value is $292.71 Mil.
Humacyte's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52 Mil.
Humacyte's current Enterprise Value is $292.71 Mil.
Humacyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humacyte Enterprise Value Related Terms
Thank you for viewing the detailed overview of Humacyte's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HUMA has been successfully added to your 